SRP-3D is under clinical development by South Rampart Pharma and currently in Phase I for Neuropathic Pain (Neuralgia). According to GlobalData, Phase I drugs for Neuropathic Pain (Neuralgia) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SRP-3D’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SRP-3D overview
SRP-3D is under development as an oral formulation for the treatment of neuropathic pain, fever, chronic pain, diabetic neuropathic pain, chemotherapy neuropathic pain and acute post operative pain, other neuropathic pain syndromes, as an ophthalmic formulation for ocular pain, as an intravenous formulation for acute pain and intravenous formulation for treatment of fever. It is an analog of 2-(benzenesulfonamide)-N-(4-hydroxyphenyl) acetamide.
South Rampart Pharma overview
South Rampart Pharma is a developer of drugs for treating acute, chronic, and neuropathic pain. The company is headquartered in New Orleans, Louisiana, the US.
For a complete picture of SRP-3D’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
